Liang Cheng

Professor and Vice Chair for Translational Research, Director of Anatomic and Molecular Pathology, Department of Pathology and Laboratory Medicine, Brown University Medical School | Lifespan Academic Medical Center (RI, USA)

Dr. Liang Cheng is the Professor and Vice Chair for Translational Research, Director of Anatomic Pathology, and Director of Molecular Pathology in the Department of Pathology and Laboratory Medicine at the Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, Rhode Island. At the age of 15, he entered the 6-year medical program in Beijing Medical University | Peking University (both China); followed by pathology residency training at Case Western Reserve University and University Hospitals Cleveland Medical Center (OH, USA) and fellowship training at the Mayo Clinic, Rochester (MN, USA). Dr. Cheng is board certified in Molecular Genetic Pathology, Anatomic and Clinical Pathology by the American Board of Pathology. Dr. Cheng has received numerous prestigious awards including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology (USCAP) and the Koss Medal Award from the International Society of Urological Pathology (ISUP) (“The medal is awarded for a lifetime achievement in the broad field of urological pathology and is the highest award bestowed by the Society”). He also received the Arthur Purdy Stout Prize from the Arthur Purdy Stout Society of Surgical Pathologists in recognition of outstanding contributions to the field of surgical pathology for a surgical pathologist less than 45 years old. Dr.Cheng has published over 1,200 peer-reviewed SCI articles (citations, >62,000; h-index: 123) in high-impact scientific journals, including British Medical Journal (BMJ) (IF 93), Nature Biotechnology (IF 68), Nature Reviews Disease Primers (IF 65), Journal of Clinical Oncology (IF 50), Annals of Oncology (IF 51), JAMA Oncology (IF 32), Science Immunology (IF 32), Molecular Cancer (IF 41), Cell Metabolism (IF 31), Gut (IF 31). Currently, he is an active member of over 30 Editorial Boards, including Mol Cancer (Associate Editor), Am J Surg Pathol, Mod Pathol, Histopathology, Hum Pathol (Senior Associate Editor), Urol Oncol, Expert Rev Precis Med (editor-in-chief), Am J Trans Res (editor-in-chief). In 2021, Dr.Cheng was ranked No. 1 among the World’s Experts in Urogenital Neoplasms. He is the President-Elect of the International Society of Urological Pathology (2023-2025). Dr. Cheng’s research focuses on translational studies of genitourinary cancers and molecular diagnostics of solid tumors (Email: [email protected]; https://vivo.brown.edu/display/lcheng26).